LUMINEX CORPORATION (NASDAQ:LMNX) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On August 7, 2017, Luminex Corporation ("the Company") issued a press release announcing its results of operations for its fiscal quarter ended June 30, 2017. A copy of the press release is furnished herewith as Exhibit99.1.
Item 2.02. Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release issued by Luminex Corporation dated August 7, 2017. |
LUMINEX CORP ExhibitEX-99.1 2 a2017-q2form8xkexhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1LUMINEX CORPORATION REPORTS SECOND QUARTER 2017 FINANCIAL RESULTSAUSTIN,…To view the full exhibit click here
About LUMINEX CORPORATION (NASDAQ:LMNX)
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease.
